Molecular genetics of prostate cancer

Genes and Development

Volumn 14, Issue 19, 2000, Pages 2410-2434

  Abate Shen, Cory ^a,b   Shen, Michael M ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; GENE PRODUCT; GROWTH FACTOR; HORMONE RECEPTOR; TELOMERASE; TRANSCRIPTION FACTOR;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; CARCINOGENESIS; CORRELATION FUNCTION; ENVIRONMENTAL FACTOR; GENE FUNCTION; GENETIC HETEROGENEITY; HORMONAL REGULATION; HUMAN; INHERITANCE; MOLECULAR GENETICS; MORPHOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATOR GENE; REVIEW;

AGING; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; MICE; MODELS, GENETIC; MOLECULAR BIOLOGY; PROSTATIC NEOPLASMS;

EID: 0034307013     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.819500     Document Type: Review

References (310)

1. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer
2. Neuroendocrine differentiation in prostatic carcinoma
3. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma
4. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer
5. Are neuro-endocrine cells of practical value as an independent prognostic parameter in prostate cancer?
6. Breast cancer risks in relatives of male breast cancer patients
7. Gut and pancreatic amine precursor uptake and decarboxylation cells are not neural crest derivatives
8. bcl-2 Overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer
9. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma
10. Neurogenic origin of human prostate endocrine cells
11. Trisomy 7: A potential cytogenetic marker of human prostate cancer progression
12. A quantitative study of serum testosterone, sex accessory organ growth, and the development of intermale aggression in the mouse
13. p53 Nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy
14. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer
15. Androgen receptors in prostate cancer
16. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma
17. Implication of cell kinetic changes during the progression of human prostatic cancer
18. Roles for Nkx3.1 in prostate development and cancer
19. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model
20. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: Simultaneous demonstration of cell-specific epithelial markers
21. p53 Is mutated in a subset of advanced-stage prostate cancers
22. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma
23. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene
24. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia
25. Prostatic intraepithelial neoplasia is a risk factor for cancer
26. Architectural patterns of high-grade prostatic intraepithelial neoplasia
27. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer
28. Overdiagnosis of prostatic adenocarcinoma
29. Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched loci of prostate carcinoma
30. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer
31. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer
32. Radiation-induced apoptosis mediated by retinoblastoma protein
33. Keratin immunoreactivity in the benign and neoplastic human prostate
34. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy
35. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens
36. An uncertain role for p53 gene alterations in human prostate cancers
37. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays
38. Prognostic significance of Bcl-2 in clinically localized prostate cancer
39. Stem cell genes in androgen-independent prostate cancer
40. Genetic epidemiology of prostate cancer in the Utah mormon genealogy
41. The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting
42. Mendelian inheritance of familial prostate cancer
43. Hereditary prostate cancer: Epidemiologic and clinical features
44. Epidemiologic evidence regarding predisposing factors to prostate cancer
45. Allelic loss of chromosomes 16q and 10q in human prostate cancer
46. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
47. Deletion mapping of chromosome 8p in colorectal carcinoma and dysplasia arising in ulcerative colitis, prostatic carcinoma, and malignant fibrous histiocytomas
48. Absence of p16/MTS1 gene mutations in human prostate cancer
49. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping
50. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer
51. p53 In prostate cancer: Frequent expressed transition mutations
52. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas
53. Prostate cancer. An overview of an increasing dilemma
54. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
55. Identification and characterization of proximal 6q deletions in prostate cancer
56. Distinct regions of allelic loss on 13q in prostate cancer
57. Distinct altered patterns of p27(KIP1) gene expression in benign prostatic hyperplasia and prostatic carcinoma
58. Association of p27(Kip1) levels with recurrence and survival in patients with stage C prostate carcinoma
59. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process
60. The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression
61. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
62. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma
63. Growth factors as mediators of androgen action during male urogenital development
64. The endocrinology and developmental biology of the prostate
65. Cellular and molecular biology of prostatic development
66. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma
67. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors
68. The epidemiology of plasma testosterone levels in middle-aged men
69. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN
70. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis
71. Prostate stem cell compartments: Expression of the cell cycle inhibitor p27(Kip1) in normal, hyperplastic, and neoplastic cells
72. Stem cell features of benign and malignant prostate epithelial cells
73. Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate
74. The multiple roles of PTEN in tumor suppression
75. Pten is essential for embryonic development and tumour suppression
76. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer
77. Approaches to the treatment of patients with hormone-sensitive prostate cancer
78. Overcoming bcl-2- and p53-mediated resistance in prostate cancer
79. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications
80. Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: A review of morphologic aspects
81. Dysregulated expression of growth factors and their receptors in the development of prostate cancer
82. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2
83. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate
84. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss
85. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis
86. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer
87. Overexpression of Cyclin D1 is associated with metastatic prostate cancer to bone
88. Haploinsufficient phenotypes in Bmp4 heterozygous null mice and modification by mutations in Gli3 and Alx4
89. Mutation of the MXI1 gene in prostate cancer
90. Association of p53 mutations with metastatic prostate cancer
91. p53 Gene alterations in human prostate carcinoma
92. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23
93. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer
94. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol
95. Laser capture microdissection
96. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia
97. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
98. PTEN and prostate cancer
99. Analysis of PTEN and the 10q23 region in primary prostate carcinomas
100. 1 is haplo-insufficient for tumour suppression
101. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice
102. Peptide growth factors and prostate cancer: New models, new opportunities
103. A 3-Mb physical map of the chromosome region 8p21.3-p22, including a 600-kb region commonly deleted in human hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer
104. Expression of bcl-2 and the progression of human and rodent prostatic cancers
105. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers
106. Mutations of the p16 gene product are rare in prostate cancer
107. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer
108. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells
109. Androgen-independent prostate cancer progression in the TRAMP model
110. Metastatic prostate cancer in a transgenic mouse
111. Histologic grading of prostate cancer: A perspective
112. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model
113. Loss of the chromosomal region 10q23-q25 in prostate cancer
114. Prostate cancer in a transgenic mouse
115. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice
116. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer
117. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer
118. Overexpression of cyclin D1 is rare in human prostate carcinoma
119. 1 protein in human prostate cancer correlates with tumor grade
120. The relationship between prostatic intraepithelial neoplasia and prostate cancer: Critical issues
121. Allelic loss of 8p sequences in prostatic intraepithelial neoplasia and carcinoma
122. Androgen-receptor gene structure and function in prostate cancer
123. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma
124. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors
125. Prognostic markers in localized prostate cancer: From microscopes to molecules
126. Morphological and functional heterogeneity in the rat prostatic gland
127. Stromal-epithelial interactions in the normal and neoplastic prostate
128. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer
129. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer
130. Immunohistochemical detection of p53 protein in human prostatic cancer
131. Distant metastases from prostatic carcinoma express androgen receptor protein
132. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death
133. Studies in prostatic cancer. I. The effects of castration, of estrogen and of androgen injection of serum phosphatases in metastatic carcinoma of the prostate
134. Suppression of metastases of rat prostatic cancer by introducing human chromosome 8
135. Integrated map of the chromosome 8p12-p21 region, a region involved in human cancers and Werner syndrome
136. Control of cell proliferation and death in the normal and neoplastic prostate: A stem cell model
137. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma
138. Etiology and disease process of benign prostatic hyperplasia
139. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostate cancers
140. Allelic loss on chromosome 10 in prostate adenocarcinoma
141. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas
142. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer
143. p16/pRb Pathway alterations are required for bypassing senescence in human prostate epithelial cells
144. Developmental patterns of plasma and testicular testosterone in mice from birth to adulthood
145. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: Relationship with apoptosis and proliferation
146. Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization
147. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes
148. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model
149. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: A model for prostate cancer
150. Point mutations of the Mxil gene are rare in prostate cancers
151. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma
152. Identification of 12p as a region of frequent deletion in advanced prostate cancer
153. Identification of two distinct tumor-suppressor loci on the long arm of chromosome 10 in small cell lung cancer
154. 1
155. Tumors associated with p53 germline mutations: A synopsis of 91 families
156. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice
157. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: Implication as a tumor suppressor
158. Androgen receptor gene and hormonal therapy failure of prostate cancer
159. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers
160. The MXI1 tumor suppressor gene is not mutated in primary prostate cancer
161. Activation of programmed cell death in the rat ventral prostate after castration
162. Localization of distant urogenital system-, central nervous system-, and endocardium-specific transcriptional regulatory elements in the GATA-3 locus
163. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone
164. Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q
165. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: Identification of three independent regions
166. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Nobel rats
167. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer
168. Essential role of mouse telomerase in highly proliferative organs
169. Identification of two distinct deleted regions on chromosome 13 in prostate cancer
170. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
171. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
172. Analysis and sorting of prostate cancer cell types by flow cytometry
173. Cell-cell interaction in prostate gene regulation and cytodifferentiation
174. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
175. ras-Induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53
176. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
177. Expression of LKB1 and PTEN tumor suppressor genes during mouse embryonic development
178. Loss of chromosome arm 8p loci in prostate cancer: Mapping by quantitative allelic imbalance
179. Precise microdissection of human prostate cancers reveals genotypic heterogeneity
180. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer
181. Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis
182. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer
183. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer
184. Role of p27 in prostate carcinogenesis
185. Prostate specific expression of Cre recombinase in transgenic mice
186. p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan
187. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene
188. Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma
189. Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization
190. Actions of estrogen in the male
191. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer
192. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage
193. Origin and development of carcinoma in the prostate
194. Origin and evolution of benign prostatic enlargement
195. Normal histology of the prostate
196. Intraductal dysplasia: A premalignant lesion of the prostate
197. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma
198. Allelic loss on chromosome 13q in human prostate carcinoma
199. Prostate cancer among the chinese: Pathologic, epidemiologic and nutritional considerations
200. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen- independence after castration in the Shionogi tumor model
201. Reduction of E-cadherin levels and deletion of the α-catenin gene in human prostate cancer cells
202. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer
203. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines
204. Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma
205. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
206. Model Systems of prostate cancer: Uses and limitations
207. p53 Protein accumulation and gene mutation in the progression of human prostate carcinoma
208. Androgen receptor gene mutations in human prostate cancer
209. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium
210. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression
211. Absence of p16(INK4) protein is restricted to the subset of lung cancer lines that retains wildtype RB
212. Molecular analysis of the INK4 family of genes in prostate carcinomas
213. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice
214. Prostate cancer progression, metastasis, and gene expression in transgenic mice
215. PTEN/MMAC1/ TEP1 involvement in primary prostate cancers
216. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis
217. Assignment of the human p27(Kip1) gene to 12p13 and its analysis in leukemias
218. Hormone resistance in prostate cancer
219. c-met proto-oncogene expression in benign and malignant human prostate tissues
220. Prostate development requires Sonic hedgehog expressed by the urogenital sinus epithelium
221. Male accessory sex organ morphogenesis is altered by loss of function of Hoxd-13
222. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
223. p27(KiP1): Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors
224. On the prevention and therapy of prostate cancer by androgen administration
225. p53 Immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma
226. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer
227. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization
228. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
229. Prostate stem cell antigen: A cell surface marker over-expressed in prostate cancer
230. Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11
231. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer
232. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients
233. Allelic loss in locally metastatic, multisampled prostate cancer
234. Genetic pattern of prostate cancer progression
235. Relationship of p21 (WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa)
236. Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas
237. Transgenic mice carrying a PSArasT24 hybrid gene develop salivary gland and gastrointestinal tract neoplasms
238. Role of Mxil in ageing organ systems and the regulation of normal and neoplastic growth
239. Tissue-specific expression of murine Nkx3.1 in the male urogenital system
240. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate
241. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: Histopathological and molecular biological alterations
242. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer
243. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma
244. Restriction of neuroblastoma to the prostate gland in transgenic mice
245. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search
246. Telomerase activity: A prevalent marker of malignant human prostate tissue
247. p53 and bcl-2 Immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy
248. Identification of a candidate tumour suppressor gene. MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
249. Morphogenesis of ductal networks in the mouse prostate
250. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway
251. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice
252. Localization of a tumor suppressor gene associated with progression of human prostate cancer within a 1.2 Mb region of 8p22-p21.3
253. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues
254. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer
255. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression
256. p16 Mutations/deletions are not frequent events in prostate cancer
257. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas
258. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
259. Ductal carcinoma in situ: Introduction of the concept of ductal intraepithelial neoplasia
260. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer
261. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate
262. Concerning a familial association between breast cancer and both prostatic and uterine malignancies
263. p53 Expression and clinical outcome in prostate cancer
264. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ
265. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
266. Androgen receptor gene expression in human prostate carcinoma cell lines
267. Ductal budding and branching patterns in the developing prostate
268. Microscopic differential diagnosis of latent carcinoma of the prostate
269. The androgen receptor: Functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines
270. Loss of heterozygosity of chromosome 8 micro-satellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer
271. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer
272. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer
273. Loss of cyclin-dependent kinase inhibitor p27(Kip1) is a novel prognostic factor in localized human prostate adenocarcinoma
274. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells
275. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer
276. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
277. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer
278. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer
279. DNA sequence amplification in human prostate cancer identified by chromosome microdis-section: Potential prognostic implications
280. Androgen receptors in endocrine-therapy-resistant human prostate cancer
281. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens
282. Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration
283. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer
284. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
285. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization
286. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation
287. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts
288. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21
289. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers
290. p53 Oncogene mutations in human prostate cancer specimens
291. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas
292. The role of Rb in sex hormone induced prostatic carcinogenesis
293. Sex hormone-induced prostatic carcinogenesis in the Noble rat: The role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer
294. Workgroup 4: Spontaneous prostate carcinoma in dogs and nonhuman primates
295. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy
296. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
297. Isolation of DICE1: A gene frequently affected by LOH and downregulated in lung carcinomas
298. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer
299. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells
300. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
301. Evidence for a prostate cancer susceptibility locus on the X chromosome
302. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer
303. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice
304. Clustered p53 immunostaining: A novel pattern associated with prostate cancer progression
305. Low p27 expression predicts poor disease-free survival in patients with prostate cancer
306. Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells
307. Loss of heterozygosity in human primary prostate carcinomas: A possible tumor suppressor gene at 7q31.1
308. Telomerase activity in prostate cancer, prostatic intra-epithelial neoplasia, and benign prostatic epithelium
309. Abnormal prostate development in C3(1)-bcl-2 transgenic mice
310. Retinoblastoma protein-dependent growth signal conflict and caspase activity are required for protein kinase C-signaled apoptosis of prostate epithelial cells